Wilms Tumor protein market
Dublin, March 31, 2026 (GLOBE NEWSWIRE) — The “Wilms Tumor Protein Market Report 2026” has been added to ResearchAndMarkets.com’s an offering. The report provides a comprehensive analysis, covering market statistics, geographic shares, competitive landscape, market segments, trends and opportunities.
The Wilms tumor protein market has shown significant growth and is expected to continue to grow in the coming years. The market size is expected to rise from $3.41 billion in 2025 to $3.61 billion in 2026, showing a compound annual growth rate (CAGR) of 5.8%. This development is driven by advances in molecular biology research, the increasing use of immunohistochemistry, the need for cancer biomarkers, advances in the production of fusion proteins, and increased investment in academic research.
Looking ahead, the market is expected to reach $4.71 billion by 2030, at a CAGR of 6.9%. This predicted growth is supported by the increasing use of precision medicine, the need for targeted cancer screening, the expansion of gene therapy research, and the integration of biomarkers into treatment planning. Key trends expected include the growing use of WT1 as a cancer biomarker, the need for molecular diagnostic tools, and an increased focus on gene expression analysis.
The increasing incidence of kidney cancer is contributing significantly to the growth of the market. Kidney cancer is characterized by abnormal growth of kidney cells, and WT1 expression plays an important role in its diagnosis. The American Cancer Society has reported about 81,800 cases of kidney cancer in 2023 alone. In addition, the estimates made by Cancer Research UK estimate 21,900 new cases annually in 2038-2040, which highlights the increasing need for Wilms tumor protein in the diagnosis.
Companies are prioritizing the development of advanced detection systems. Charles River Laboratories announced an ELISA Kit in February 2023 for the detection and measurement of residual host cell proteins (HCPs), using Avian IgY antibodies from SPF hens’ eggs. This finding shows commitment to the accuracy of protein detection.
Major market players include Thermo Fisher Scientific, Abcam plc, BioLegend Inc., Cell Signaling Technology, and others. In December 2023, Danaher Corporation purchased Abcam plc for $5.7 billion, with the goal of leveraging Abcam’s advanced antibody platform to strengthen its life sciences offerings.
As of 2025, North America held the largest share in the Wilms tumor protein market. Areas covered include Asia-Pacific, Western and Eastern Europe, South America, and others, with major presence in countries such as the USA, UK, Canada, China and Germany.
#Wilms #Tumor #Protein #Market #Outlook #Shows #CAGR #Increasing #Investment #Oncology #Research #Accelerates #Industry #Growth